Osteoarthritis Progression And Sensory Pathway Alterations
骨关节炎进展和感觉通路改变
基本信息
- 批准号:10169854
- 负责人:
- 金额:$ 16.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-15 至 2021-03-31
- 项目状态:已结题
- 来源:
- 关键词:Afferent NeuronsAnalgesicsAnatomyC FiberChronicChronic DiseaseClinicalDegenerative polyarthritisDevelopmentDiseaseEsthesiaEvolutionFiberGenerationsHealthImageJointsKneeKnee jointMaintenanceMechanoreceptorsMedial meniscus structureMediatingMedicalMicroscopyModelingMusNGFR ProteinNatureNerveNeurobiologyNeuronal PlasticityNeuronsNociceptionNociceptorsPainParvalbuminsPathologyPathway interactionsPatientsPatternPeripheralReporterRestSensoryTRPV1 geneTechniquesTherapeuticTherapeutic AgentsTherapeutic InterventionTranslatingWeight-Bearing statebasecentral sensitizationdorsal hornin vivojoint injuryjoint mobilizationnerve supplynovelnovel strategiesnovel therapeuticsosteoarthritis painpain behaviortargeted treatment
项目摘要
Project Summary
There is an urgent need for new therapeutic agents that treat the pain associated with osteoarthritis (OA). OA
is a chronic disease, and as disease progresses, patients can describe different types of pain, including pain
on weightbearing or joint movement, and pain at rest. Some patients display signs of peripheral and/or central
sensitization. Compelling clinical evidence suggests that ongoing peripheral input from the OA joint drives pain
and sensitization. We have developed the murine DMM (destabilization of the medial meniscus) model to study
the chronic nature of the disease and the different pain behaviors associated with progressive joint damage.
The overarching aim is to characterize anatomical and functional alterations in the sensory innervation of the
joint. We have uncovered that in the course of experimental OA, NaV1.8 nociceptors undergo profound, and
previously unappreciated, plasticity at all levels (in the knee joint, in the DRG, and in the dorsal horn) in a
precisely evolving manner. Recently, it has become clear that sensory neurons can be classified based on
unique patterns of expression of molecules that underlie different aspects of somatic sensation. Specifically,
NaV1.8 neurons comprise distinct functional subsets, including heat-sensitive TRPV1 neurons,
mechanosensitive Mrgprd C-fibers, TH+ C-low threshold mechanoreceptors (C-LTMR), and silent CHRNA3
fibers. Another subset of potential relevance to OA pain is TrkA+, expressing the receptor for Nerve Growth
Factor. We hypothesize that specific temporospatial changes in these subpopulations mediate the evolution of
pain behaviors during OA progression. Our experimental plan considers two complementary aims to study (1)
temporal and spatial contributions (which nerves are present and functional in the OA joint, where and when?);
and (2) how we may target these specific neuronal subsets to examine effects on pain behaviors and joint
health. Specific Aim 1 aims to define temporal and spatial neuroplasticity of knee innervation in the context of
OA joint pathology and pain. We have used a variety of Cre/Flp drivers to produce lines of fluorescent reporter
mice specific for distinct subsets of nociceptive, mechanosensitive, and proprioceptive (parvalbumin, PV) DRG
neurons. We will use these mice to define anatomical and functional changes in knee innervation, using
confocal and lightsheet microscopy, in vivo Ca2+ imaging, and transient chemogenetic silencing of specific
neuronal subsets. Specific Aim 2 aims to target specific neuronal subsets and examine the effect on OA
disease (pain and joint damage), in order to explore how our findings may translate to new approaches for OA
pain. We will determine the effects of chronic chemogenetic silencing of neuronal subpopulations on OA pain
and joint damage. We will also study the “receptome” specific to DRG subpopulations in order to develop
targeted therapeutic interventions. We propose that the identification of neuronal subpopulations that mediate
OA pain behaviors will allow them to be specifically targeted at specific stages of the disease and this will
result in novel, more efficacious and safer therapeutic approaches to OA pain.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD J MILLER其他文献
RICHARD J MILLER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD J MILLER', 18)}}的其他基金
Small molecule CXCR4 modulators as molecular probes for studying AML
小分子 CXCR4 调节剂作为研究 AML 的分子探针
- 批准号:
9099791 - 财政年份:2015
- 资助金额:
$ 16.28万 - 项目类别:
Osteoarthritis Progression and Sensory Pathway Alterations
骨关节炎进展和感觉通路改变
- 批准号:
8829147 - 财政年份:2013
- 资助金额:
$ 16.28万 - 项目类别:
Osteoarthritis Progression and Sensory Pathway Alterations
骨关节炎进展和感觉通路改变
- 批准号:
9053984 - 财政年份:2013
- 资助金额:
$ 16.28万 - 项目类别:
Osteoarthritis Progression And Sensory Pathway Alterations
骨关节炎进展和感觉通路改变
- 批准号:
9757504 - 财政年份:2013
- 资助金额:
$ 16.28万 - 项目类别:
Osteoarthritis Progression And Sensory Pathway Alterations
骨关节炎进展和感觉通路改变
- 批准号:
8480989 - 财政年份:2013
- 资助金额:
$ 16.28万 - 项目类别:
Osteoarthritis Progression and Sensory Pathway Alterations
骨关节炎进展和感觉通路改变
- 批准号:
8655517 - 财政年份:2013
- 资助金额:
$ 16.28万 - 项目类别:
Osteoarthritis Progression And Sensory Pathway Alterations
骨关节炎进展和感觉通路改变
- 批准号:
10380166 - 财政年份:2013
- 资助金额:
$ 16.28万 - 项目类别:
Osteoarthritis Progression And Sensory Pathway Alterations
骨关节炎进展和感觉通路改变
- 批准号:
10626714 - 财政年份:2013
- 资助金额:
$ 16.28万 - 项目类别:
相似海外基金
Planning Study for the Development of Sigma 2 ligands as Analgesics
Sigma 2 配体镇痛药开发规划研究
- 批准号:
10641500 - 财政年份:2023
- 资助金额:
$ 16.28万 - 项目类别:
Designing and validating optimal nonaddictive analgesics using the CANDO paradigm
使用 CANDO 范式设计和验证最佳的非成瘾性镇痛药
- 批准号:
10485593 - 财政年份:2023
- 资助金额:
$ 16.28万 - 项目类别:
Identification of botanical hHv1 channel blockers as analgesics for neuropathic pain
植物 hHv1 通道阻滞剂作为神经性疼痛镇痛药的鉴定
- 批准号:
10728526 - 财政年份:2023
- 资助金额:
$ 16.28万 - 项目类别:
Development of LPA5 Antagonists as Analgesics
LPA5 拮抗剂镇痛药的开发
- 批准号:
10638278 - 财政年份:2023
- 资助金额:
$ 16.28万 - 项目类别:
Designed Multiple Ligands as Non-opioid Analgesics for Treating Chronic Pain
设计多种配体作为非阿片类镇痛药,用于治疗慢性疼痛
- 批准号:
10621646 - 财政年份:2023
- 资助金额:
$ 16.28万 - 项目类别:
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
- 批准号:
10425794 - 财政年份:2022
- 资助金额:
$ 16.28万 - 项目类别:
Elucidation of the mechanism of pain suppression by exercise and development of new analgesics
阐明运动镇痛机制及开发新型镇痛药
- 批准号:
22K19602 - 财政年份:2022
- 资助金额:
$ 16.28万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Allosteric Targeting of Cannabinoid CB1 Receptor to Develop Non-Addictive Small Molecule Analgesics
大麻素 CB1 受体变构靶向开发非成瘾性小分子镇痛药
- 批准号:
10512672 - 财政年份:2022
- 资助金额:
$ 16.28万 - 项目类别:
A novel clinically-relevant mouse model of chronic overlapping pain conditions for screening analgesics
用于筛选镇痛药的新型临床相关慢性重叠疼痛小鼠模型
- 批准号:
10821681 - 财政年份:2022
- 资助金额:
$ 16.28万 - 项目类别:
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
- 批准号:
10721752 - 财政年份:2022
- 资助金额:
$ 16.28万 - 项目类别:














{{item.name}}会员




